-
Impax EVP finance, CFO resigns
HAYWARD, Calif. — One of Impax Labs' top executives is leaving the company, the drug maker announced Friday.
Impax said EVP finance and CFO Arthur Koch would resign to pursue other opportunities. VP finance Bryan Reasons has been appointed acting CFO as the company searches for a successor to Koch.
-
Mylan launches thiamine-deficiency drug
PITTSBURGH — Mylan has launched a generic drug for treating thiamine deficiency, the company said Thursday.
The generic drug maker announced the launch of thiamine hydrochloride injection in the 100-mg-per-mL strength, packaged in 25-vial packs of 200-mg-per-2-mL multiple-dose vials.
The drug had sales of about $18.6 million during the 12-month period ended in March, according to IMS Health. Mylan said it would ship the drug immediately.